NCT06669247View on ClinicalTrials.gov

A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

186

Participants

Timeline

Start Date

December 11, 2024

Primary Completion Date

November 11, 2033

Study Completion Date

November 1, 2035

Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
DRUG

Linvoseltamab

Administered per protocol

DRUG

REGN7945+Linvoseltamab

Administered per protocol

Trial Locations (7)

2500

RECRUITING

Illawarra Cancer Care Centre, Wollongong

3004

RECRUITING

Alfred Hospital, Melbourne

3065

RECRUITING

St Vincent's Hospital - Melbourne, Fitzroy

4217

RECRUITING

Pindara Private Hospital, Benowa

5000

RECRUITING

Royal Adelaide Hospital, Adelaide

NW1 2PG

RECRUITING

University College London Hospitals, London

M20 4BQ

RECRUITING

The Christie NHS Foundation Trust, Manchester

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY